Elbit Systems: Strong Q1, But Valuation Still Looks Stretched

Elbit Systems posted strong Q1 2026 results, with revenue up 15.5% year over year, non-GAAP EPS beating by $0.54, and margins expanding to 10.1%. Backlog hit a record $30.2B, with 71% international, supporting visibility into future growth despite higher capex and R&D spending. The stock already trades at 51x earnings and 32x EV/EBITDA, indicating the market is pricing in sustained execution and backlog conversion.

Analysis

This print is not just a beat; it extends the duration of the bull case by showing the business can compound earnings while still reinvesting. The market is likely underappreciating the mix shift inside the backlog: a higher international share reduces reliance on any single defense budget cycle, but it also raises execution and FX complexity, so the premium multiple is effectively pricing a cleaner conversion path than the historical reality usually delivers.

Second-order winners are the company’s upstream niche suppliers and domestic defense peers that can piggyback on a stronger procurement cadence, but the more interesting effect is on competitors bidding for the same programs. A record backlog at this margin profile can force rivals to either defend share with lower pricing or accept slower book-to-bill, which is bullish for the overall sector’s pricing discipline over the next 2-4 quarters.

The key risk is not demand but disappointment against an elevated setup. At 51x earnings, even a modest slowdown in backlog conversion, a one-quarter margin giveback from higher R&D/capex, or a delay in international contract funding could compress multiple quickly over the next 1-3 months. The strongest contrarian argument is that this may be a quality-duration trade rather than a classic earnings re-rating: if growth normalizes but the multiple stays anchored, forward returns become highly dependent on uninterrupted execution.

What the consensus may be missing is that defense leaders often trade like infrastructure monopolies only until the market starts discounting capex intensity. If management’s reinvestment is required to sustain backlog growth, near-term free cash flow optics can lag EPS and create a window for volatility even while the fundamental story remains intact. That makes the stock attractive on pullbacks, but vulnerable to any guidance nuance that implies the current growth rate is not the new floor.

Key Decisions for Investors

• Stay long ESLT on pullbacks over the next 1-3 weeks, but size it as a momentum-with-execution position rather than a deep value trade; upside remains intact if backlog conversion stays >1x revenue, but the multiple leaves little room for a miss.
• Pair trade: long ESLT / short a lower-quality defense OEM over the next 1-2 quarters to express preference for backlog visibility and margin durability; the relative trade should work even if the sector de-rates modestly.
• Consider buying 3-6 month out-of-the-money puts against a small ESLT core long into the next earnings window as a hedge; the risk/reward favors protection because premium compression can outpace fundamental deterioration if guidance softens.
• For investors seeking the second-order winner, look at selected suppliers tied to Israeli defense production or international systems integration for a 6-12 month trade; they should benefit from the same demand cycle without ESLT’s valuation overhang.
• Avoid chasing at current levels unless you have high conviction in multi-quarter backlog conversion; the better entry is typically after a 8-12% drawdown or after the market confirms that capex/R&D is translating into sustained FCF.